Browsing by Keyword : Sodium-Glucose Transporter 2 Inhibitors
Showing results 16 to 23 of 23
Pub Year | | Title | AJOU Author(s) |
2022 | | Healthcare resource utilization in patients treated with empagliflozin in East Asia | 김대중, 하경화 |
2021 | | Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study | 김대중, 하경화 |
2023 | | Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study | 김대중 |
2018 | | Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy | 송지훈, 이기황, 정유리 |
2020 | | Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study | 김대중 |
2024 | | SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea | 김순선, 정재연, 조효정 |
2018 | | Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study | 김대중, 김혜진, 이관우, 전자영, 한승진 |
2022 | | Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study | 김대중, 최용준, 하경화 |
1